OnDemand

The growth of specialty and specialty-lite drugs means that manufacturers have to contend with channel design and pricing challenges as they approach commercialization and beyond. In addition, manufacturers launching their first specialty-lite drug must understand how this affects their gross-to-net (GTN) when compared to traditional specialty launches.

Jennifer Sharpe, Vice President of Gross-to-Net Consulting and Reena Patel, Partner at Blue Fin Group discussed the following:

• The difference between specialty and specialty-lite drug therapies
• The nuance of specialty-lite drugs as it relates to GTN when compared to specialty drugs
• Considerations for channel strategies and WAC price
• Forecasting methodologies for specialty-lite drugs

Jennifer Sharpe
Vice President, Gross-To-Net Consulting

Reena Patel
Partner, Blue Fin Group